1. Clinical & Scientific Overview
Olmesartan Medoxomil (TIP-MED-000004, Reference Code [3.4]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Angiotensin II Receptor Blocker (ARB) (Ester Prodrug).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Olmezest (Sun Pharma), Olmy (Zydus), Olmecip (Cipla), Olsar (Unichem)
Oral Film-Coated Tablets: 10 mg, 20 mg, 40 mg
3. Mechanism of Action & Pharmacodynamics
Angiotensin II Receptor Blocker (ARB) (Ester Prodrug) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Angiotensin II Receptor Blocker (ARB) (Ester Prodrug) for Essential hypertension (monotherapy or in combination with amlodipine/chlorthalidone)..
4. Therapeutic Indications & Evidence-Supported Uses
- Essential hypertension (monotherapy or in combination with amlodipine/chlorthalidone)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Initially 20 mg once daily; may increase to 40 mg once daily after 2 weeks if additional BP reduction is needed (Max 40 mg/day). In elderly or renal impairment (CrCl 20–60 mL/min): start at 10–20 mg OD.
Administration & Meal Timing: With or without food. | Once daily at the same time each morning.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Dosing depends on renal function; in severe renal impairment (CrCl <20 mL/min), do not exceed 20 mg once daily. Monitor creatinine and K+. Hepatic: No adjustment in mild hepatic impairment; avoid in severe hepatic impairment or biliary obstruction.
Renal: Dosing depends on renal function; in severe renal impairment (CrCl <20 mL/min), do not exceed 20 mg once daily. Monitor creatinine and K+. Hepatic: No adjustment in mild hepatic impairment; avoid in severe hepatic impairment or biliary obstruction.
Renal: Dosing depends on renal function; in severe renal impairment (CrCl <20 mL/min), do not exceed 20 mg once daily. Monitor creatinine and K+. Hepatic: No adjustment in mild hepatic impairment; avoid in severe hepatic impairment or biliary obstruction.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in pregnancy, biliary obstruction, and co-administration with aliskiren in diabetes. Specific regulatory warning: Sprue-like enteropathy (severe chronic diarrhoea with substantial weight loss occurring months to years after starting olmesartan).
Key Clinical Precautions: Renal: Dosing depends on renal function; in severe renal impairment (CrCl <20 mL/min), do not exceed 20 mg once daily. Monitor creatinine and K+. Hepatic: No adjustment in mild hepatic impairment; avoid in severe hepatic impairment or biliary obstruction.
8. Adverse Effects Profile
- Dizziness, headache, mild hyperuricaemia, pharyngitis, diarrhoea.
- Olmesartan-induced sprue-like enteropathy (villous atrophy mimicking celiac disease), severe hyperkalaemia, acute kidney injury, symptomatic hypotension.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Colesevelam (bile acid sequestrant) reduces olmesartan bioavailability—administer olmesartan ≥4 hours before colesevelam
- NSAIDs, potassium supplements, and spironolactone carry standard ARB interaction risks
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Specifically instruct the patient and family that if unexplained severe chronic watery diarrhoea and weight loss develop—even after taking olmesartan safely for 1–2 years—they must report to the physician immediately so the drug can be switched.
- Meal & Clock Timing Instruction: With or without food. (Once daily at the same time each morning.)
- Missed Dose Protocol: Take as soon as remembered on the same day; skip if almost time for the next dose.
- Geriatric Dispensing Pearl: Potent antihypertensive effect; initiate at 10 mg or 20 mg in elderly CGHS patients to avoid rapid postural blood pressure drops. Always inquire about chronic diarrhoea during repeat refills.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 10 mg, 20 mg, 40 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.4] (p. 22)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.6] Enalapril Maleate — Angiotensin-Converting Enzyme (ACE) Inhibitor (Prodrug converted
- [3.7] Metoprolol (Metoprolol Succinate ER & Metoprolol Tartrate IR) — Cardioselective Beta-1 Adrenergic Blocker
- [3.8] Atenolol — Hydrophilic Cardioselective Beta-1 Adrenergic Blocker
- [3.9] Carvedilol — Non-Selective Beta-1/Beta-2 and Alpha-1 Adrenergic Blocker; Antio
